Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial

F. Behrens, P. Sewerin, E. de Miguel, Y. Patel, A. Batalov, E. Dokoupilova, C. Kleinmond, E. Pournara, A. Shekhawat, C. Jentzsch, A. Wiedon, X. Baraliakos, ACHILLES study group

. 2022 ; 61 (7) : 2856-2866. [pub] 20220706

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025265

OBJECTIVE: ACHILLES aimed to demonstrate efficacy of secukinumab on Achilles' tendon enthesitis in spondyloarthritis (SpA) patients. METHODS: Patients ≥18 years (n = 204) with active PsA or axial SpA and heel enthesitis were randomized 1:1 to secukinumab 150/300 mg or placebo up to week 24, and thereafter placebo patients were switched to secukinumab. RESULTS: At week 24, a higher, yet statistically non-significant (P = 0.136), proportion of patients in secukinumab vs placebo reported resolution of Achilles tendon enthesitis in affected foot (42.2% vs 31.4%; odds ratio [OR] = 1.63; 95% CI: 0.87, 3.08). Proportion of patients reporting resolution of enthesitis based on Leeds Enthesitis Index was higher with secukinumab vs placebo (33.3% vs 23.5%; OR = 1.65; 95% CI: 0.85, 3.25) at week 24. Mean change from baseline in heel pain at week 24 was higher in secukinumab patients vs placebo (-2.8 [3.0] vs -1.9 [2.7]). Greater improvements with secukinumab were observed in heel enthesopathy activity and global assessment of disease activity. Imaging evaluation by local reading confirmed heel enthesitis on MRI at screening for all patients. Based on central reading, 56% presented with bone marrow oedema and/or tendinitis; according to Heel Enthesitis MRI Scoring System (HEMRIS) post hoc analysis, 76% had signs of entheseal inflammation while 86% had entheseal inflammation and/or structural changes. CONCLUSION: A substantial proportion of patients showed no signs of inflammation on the centrally read MRIs despite a clinical diagnosis of heel enthesitis, thus highlighting that the discrepancy between the clinical and imaging assessments of enthesitis requires further investigation. Although ACHILLES did not meet the primary end point, the study reported clinically meaningful improvements in patient-related outcomes. TRIAL REGISTRATION: clinicaltrials.gov, NCT02771210.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025265
003      
CZ-PrNML
005      
20221031100140.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/keab784 $2 doi
035    __
$a (PubMed)34730795
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Behrens, Frank $u CIRI/Rheumatology and Fraunhofer Institute for Translationale Medicine & Pharmacology (ITMP) and Cluster of Excellence Immune-Mediated Diseases (CIMD), Goethe-University, Frankfurt $1 https://orcid.org/0000000187507186
245    10
$a Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial / $c F. Behrens, P. Sewerin, E. de Miguel, Y. Patel, A. Batalov, E. Dokoupilova, C. Kleinmond, E. Pournara, A. Shekhawat, C. Jentzsch, A. Wiedon, X. Baraliakos, ACHILLES study group
520    9_
$a OBJECTIVE: ACHILLES aimed to demonstrate efficacy of secukinumab on Achilles' tendon enthesitis in spondyloarthritis (SpA) patients. METHODS: Patients ≥18 years (n = 204) with active PsA or axial SpA and heel enthesitis were randomized 1:1 to secukinumab 150/300 mg or placebo up to week 24, and thereafter placebo patients were switched to secukinumab. RESULTS: At week 24, a higher, yet statistically non-significant (P = 0.136), proportion of patients in secukinumab vs placebo reported resolution of Achilles tendon enthesitis in affected foot (42.2% vs 31.4%; odds ratio [OR] = 1.63; 95% CI: 0.87, 3.08). Proportion of patients reporting resolution of enthesitis based on Leeds Enthesitis Index was higher with secukinumab vs placebo (33.3% vs 23.5%; OR = 1.65; 95% CI: 0.85, 3.25) at week 24. Mean change from baseline in heel pain at week 24 was higher in secukinumab patients vs placebo (-2.8 [3.0] vs -1.9 [2.7]). Greater improvements with secukinumab were observed in heel enthesopathy activity and global assessment of disease activity. Imaging evaluation by local reading confirmed heel enthesitis on MRI at screening for all patients. Based on central reading, 56% presented with bone marrow oedema and/or tendinitis; according to Heel Enthesitis MRI Scoring System (HEMRIS) post hoc analysis, 76% had signs of entheseal inflammation while 86% had entheseal inflammation and/or structural changes. CONCLUSION: A substantial proportion of patients showed no signs of inflammation on the centrally read MRIs despite a clinical diagnosis of heel enthesitis, thus highlighting that the discrepancy between the clinical and imaging assessments of enthesitis requires further investigation. Although ACHILLES did not meet the primary end point, the study reported clinically meaningful improvements in patient-related outcomes. TRIAL REGISTRATION: clinicaltrials.gov, NCT02771210.
650    _2
$a Achillova šlacha $7 D000125
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    12
$a humanizované monoklonální protilátky $x škodlivé účinky $7 D061067
650    12
$a entezopatie $x farmakoterapie $7 D000070676
650    _2
$a lidé $7 D006801
650    _2
$a zánět $7 D007249
650    12
$a spondylartritida $x farmakoterapie $7 D025241
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Sewerin, Philipp $u Department of Rheumatology & Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany $1 https://orcid.org/0000000184656207
700    1_
$a de Miguel, Eugenio $u Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain $1 https://orcid.org/0000000151461964
700    1_
$a Patel, Yusuf $u Hull University Teaching Hospitals, Hull, UK
700    1_
$a Batalov, Anastas $u Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria $1 https://orcid.org/0000000188570574
700    1_
$a Dokoupilova, Eva $u Faculty of Pharmacy, Department of Pharmaceutical Technology, Medical Plus, s.r.o., Uherske Hradiste; Masaryk University, Brno, Czech Republic
700    1_
$a Kleinmond, Christine $u ClinProject GmbH, Eurasburg, Germany
700    1_
$a Pournara, Effie $u Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
700    1_
$a Shekhawat, Ankita $u Novartis Healthcare Pvt. Ltd, Hyderabad, India
700    1_
$a Jentzsch, Claudia $u Novartis Pharma GmbH, Nürnberg
700    1_
$a Wiedon, Annette $u Novartis Pharma GmbH, Nürnberg
700    1_
$a Baraliakos, Xenofon $u Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany $1 https://orcid.org/0000000294759362
710    2_
$a ACHILLES study group
773    0_
$w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 61, č. 7 (2022), s. 2856-2866
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34730795 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100137 $b ABA008
999    __
$a ok $b bmc $g 1854791 $s 1176555
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 61 $c 7 $d 2856-2866 $e 20220706 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace